The non-structural proteins of RSV: Targeting interferon antagonists for vaccine development

Infectious Disorders - Drug Targets

Volumn 12, Issue 2, 2012, Pages 129-137

  Teng, Michael N ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Interferon; Live attenuated vaccines; Mutagenesis; Nonstructural proteins; Recombinant virus; Viral replication

Indexed keywords

INTERFERON; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VACCINE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENETIC ANALYSIS; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIFE CYCLE ASSESSMENT; MUTATIONAL ANALYSIS; NONHUMAN; PNEUMOVIRUS INFECTION; PROTEIN FUNCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS REPLICATION;

EID: 84860271918     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612800100170     Document Type: Review

References (101)

1. Glezen, W. P.; Taber, L. H.; Frank, A. L.; Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child, 1986, 140(6), 543-546.
2. Anderson, L. J.; Parker, R. A.; Strikas, R. L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis., 1990, 161(4), 640-646.
3. Paramore, L. C.; Ciuryla, V.; Ciesla, G.; Liu, L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics, 2004, 22(5), 275-284.
4. Shay, D. K.; Holman, R. C.; Newman, R. D.; Liu, L. L.; Stout, J. W.; Anderson, L. J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA, 1999, 282(15), 1440-1446.
5. Shay, D. K.; Holman, R. C.; Roosevelt, G. E.; Clarke, M. J.; Anderson, L. J. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis., 2001, 183(1), 16-22.
6. Altman, C. A.; Englund, J. A.; Demmler, G.; Drescher, K. L.; Alexander, M. A.; Watrin, C.; Feltes, T. F. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr. Cardiol., 2000, 21(5), 433-438.
7. Huang, M.; Bigos, D.; Levine, M. Ventricular arrhythymia associated with respiratory syncytial viral infection. Pediatr. Cardiol., 1998, 19(6), 498-500.
8. Yount, L. E.; Mahle, W. T. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics, 2004, 114(6), 1606-11.
9. Kaneko, M.; Watanabe, J.; Ueno, E.; Hida, M.; Sone, T. Risk factors for severe respiratory syncytial virus-associated lower respiratory tract infection in children. Pediatr. Int., 2001, 43(5), 489-492.
10. Collins, P. L.; Chanock, R. M.; Murphy, B. R. Respiratory syncytial virus. In: Fields Virology, Fourth ed.; Knipe, D. M.; Howley, P. M. Eds. Lippincott, Williams and Wilkins: Philadelphia, 2001; pp 1443-1485.
11. thed.; Knipe, D. M.; Howley, P. M.; Griffin, D. E.; Lamb, R. A.; Martin, M. A.; Roizman, B.; Straus, S. E. Eds., Lippincott Williams & Wilkins: 2007.
12. Marchant, A.; Goetghebuer, T.; Ota, M. O.; Wolfe, I.; Ceesay, S. J.; De Groote, D.; Corrah, T.; Bennett, S.; Wheeler, J.; Huygen, K.; Aaby, P.; McAdam, K. P.; Newport, M. J. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J. Immunol., 1999, 163(4), 2249-2255.
13. Vekemans, J.; Amedei, A.; Ota, M. O.; D'Elios, M. M.; Goetghebuer, T.; Ismaili, J.; Newport, M. J.; Del Prete, G.; Goldman, M.; McAdam, K. P.; Marchant, A. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur. J. Immunol., 2001, 31(5), 1531-1535.
14. Stensballe, L. G.; Nante, E.; Jensen, I. P.; Kofoed, P. E.; Poulsen, A.; Jensen, H.; Newport, M.; Marchant, A.; Aaby, P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine, 2005, 23(10), 1251-1257.
15. Panda, A.; Arjona, A.; Sapey, E.; Bai, F.; Fikrig, E.; Montgomery, R. R.; Lord, J. M.; Shaw, A. C. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol., 2009, 30(7), 325-333.
16. Fujihashi, K.; Kiyono, H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol., 2009, 30(7), 334-343.
17. Chen, W. H.; Kozlovsky, B. F.; Effros, R. B.; Grubeck-Loebenstein, B.; Edelman, R.; Sztein, M. B. Vaccination in the elderly: an immunological perspective. Trends Immunol., 2009, 30(7), 351-359.
18. Fulton, R. B.; Varga, S. M. Effects of aging on the adaptive immune response to respiratory virus infections. Aging Health, 2009, 5(6), 775.
19. Sambhara, S.; McElhaney, J. E. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol., 2009, 333, 413-429.
20. Siegrist, C. A.; Aspinall, R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol., 2009, 9(3), 185-194.
21. Siegrist, C. A. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol., 2007, 137 (Suppl 1), S4-9.
22. Morein, B.; Blomqvist, G.; Hu, K. Immune responsiveness in the neonatal period. J. Comp. Pathol., 2007, 137 (Suppl 1), S27-31.
23. Williams, J. V.; Weitkamp, J. H.; Blum, D. L.; LaFleur, B. J.; Crowe, J. E. Jr. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. Mol. Immunol., 2009, 47(2-3), 407-414.
24. Kapikian, A. Z.; Mitchell, R. H.; Chanock, R. M.; Shvedoff, R. A.; Stewart, C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol., 1969, 89(4), 405-421.
25. Kim, H. W.; Canchola, J. G.; Brandt, C. D.; Pyles, G.; Chanock, R. M.; Jensen, K.; Parrott, R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol., 1969, 89(4), 422-434.
26. Kim, H. W.; Arrobio, J. O.; Brandt, C. D.; Wright, P.; Hodes, D.; Chanock, R. M.; Parrott, R. H. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics, 1973, 52(1), 56-63.
27. Castilow, E. M.; Olson, M. R.; Varga, S. M. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res., 2007, 39(1-3), 225-239.
28. Delgado, M. F.; Polack, F. P. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev. Vaccines, 2004, 3(6), 693-700.
29. Delgado, M. F.; Coviello, S.; Monsalvo, A. C.; Melendi, G. A.; Hernandez, J. Z.; Batalle, J. P.; Diaz, L.; Trento, A.; Chang, H. Y.; Mitzner, W.; Ravetch, J.; Melero, J. A.; Irusta, P. M.; Polack, F. P. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med., 2009, 15(1), 34-41.
30. Wright, P. F.; Karron, R. A.; Belshe, R. B.; Thompson, J.; Crowe, J. E., Jr.; Boyce, T. G.; Halburnt, L. L.; Reed, G. W.; Whitehead, S. S.; Anderson, E. L.; Wittek, A. E.; Casey, R.; Eichelberger, M.; Thumar, B.; Randolph, V. B.; Udem, S. A.; Chanock, R. M.; Murphy, B. R. Evaluation of a live, cold-passaged, temperaturesensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis., 2000, 182(5), 1331-142.
31. Wright, P. F.; Shinozaki, T.; Fleet, W.; Sell, S. H.; Thompson, J.; Karzon, D. T. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr., 1976, 88(6), 931-936.
32. Karron, R. A.; Buonagurio, D. A.; Georgiu, A. F.; Whitehead, S. S.; Adamus, J. E.; Clements-Mann, M. L.; Harris, D. O.; Randolph, V. B.; Udem, S. A.; Murphy, B. R.; Sidhu, M. S. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA, 1997, 94(25), 13961-1396.
33. Karron, R. A.; Wright, P. F.; Belshe, R. B.; Thumar, B.; Casey, R.; Newman, F.; Polack, F. P.; Randolph, V. B.; Deatly, A.; Hackell, J.; Gruber, W.; Murphy, B. R.; Collins, P. L. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis., 2005, 191(7), 1093-1104.
34. Karron, R. A.; Wright, P. F.; Crowe, J. E., Jr.; Clements-Mann, M. L.; Thompson, J.; Makhene, M.; Casey, R.; Murphy, B. R. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis., 1997, 176(6), 1428-1436.
35. Johnson, P. R. Jr.; Feldman, S.; Thompson, J. M.; Mahoney, J. D.; Wright, P. F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J. Med. Virol., 1985, 17(4), 325-335.
36. Johnson, P. R.; Feldman, S.; Thompson, J. M.; Mahoney, J. D.; Wright, P. F. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J. Infect. Dis., 1986, 154(1), 121-127.
37. Mills, J. t.; Van Kirk, J. E.; Wright, P. F.; Chanock, R. M. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J. Immunol., 1971, 107(1), 123-130.
38. Polack, F. P.; Karron, R. A. The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J., 2004, 23(1 Suppl), S65-73.
39. Collins, P. L.; Whitehead, S. S.; Bukreyev, A.; Fearns, R.; Teng, M. N.; Juhasz, K.; Chanock, R. M.; Murphy, B. R. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv. Virus Res., 1999, 54, 423-451.
40. Pringle, C. R.; Filipiuk, A. H.; Robinson, B. S.; Watt, P. J.; Higgins, P.; Tyrrell, D. A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine, 1993, 11(4), 473-478.
41. Wright, P. F.; Mills, J.; Chanock, R. M. Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J. Infect. Dis., 1971, 124(5), 505-511.
42. Wright, P. F.; Belshe, R. B.; Kim, H. W.; Van Voris, L. P.; Chanock, R. M. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun., 1982, 37(1), 397-400.
43. Wright, P. F.; Karron, R. A.; Belshe, R. B.; Shi, J. R.; Randolph, V. B.; Collins, P. L.; O'Shea, A. F.; Gruber, W. C.; Murphy, B. R. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine, 2007, 25(42), 7372-7378.
44. Whitehead, S. S.; Firestone, C. Y.; Karron, R. A.; Crowe, J. E. Jr.; Elkins, W. R.; Collins, P. L.; Murphy, B. R. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J. Virol., 1999, 73(2), 871-877.
45. Goodbourn, S.; Randall, R. E. The regulation of type I interferon production by paramyxoviruses. J. Interferon. Cytokine Res., 2009, 29(9), 539-547.
46. Pichlmair, A.; Schulz, O.; Tan, C. P.; Naslund, T. I.; Liljestrom, P.; Weber, F.; Reis e Sousa, C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science, 2006, 314(5801), 997-1001.
47. Hornung, V.; Ellegast, J.; Kim, S.; Brzozka, K.; Jung, A.; Kato, H.; Poeck, H.; Akira, S.; Conzelmann, K. K.; Schlee, M.; Endres, S.; Hartmann, G. 5'-Triphosphate RNA is the ligand for RIG-I. Science, 2006, 314(5801), 994-997.
48. Meylan, E.; Tschopp, J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell, 2006, 22(5), 561-569.
49. Yoneyama, M.; Kikuchi, M.; Natsukawa, T.; Shinobu, N.; Imaizumi, T.; Miyagishi, M.; Taira, K.; Akira, S.; Fujita, T. The RNA helicase RIG-I has an essential function in double-stranded RNAinduced innate antiviral responses. Nat. Immunol., 2004, 5(7), 730-737.
50. Fitzgerald, K. A.; McWhirter, S. M.; Faia, K. L.; Rowe, D. C.; Latz, E.; Golenbock, D. T.; Coyle, A. J.; Liao, S. M.; Maniatis, T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol., 2003, 4(5), 491-496.
51. Sato, S.; Sugiyama, M.; Yamamoto, M.; Watanabe, Y.; Kawai, T.; Takeda, K.; Akira, S. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol., 2003, 171(8), 4304-4310.
52. Jounai, N.; Takeshita, F.; Kobiyama, K.; Sawano, A.; Miyawaki, A.; Xin, K. Q.; Ishii, K. J.; Kawai, T.; Akira, S.; Suzuki, K.; Okuda, K. The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl. Acad. Sci. USA, 2007, 104(35), 14050-14055.
53. Zeng, W.; Sun, L.; Jiang, X.; Chen, X.; Hou, F.; Adhikari, A.; Xu, M.; Chen, Z. J. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell, 2010, 141(2), 315-330.
54. Hiscott, J.; Grandvaux, N.; Sharma, S.; Tenoever, B. R.; Servant, M. J.; Lin, R. Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann. N. Y. Acad. Sci., 2003, 1010, 237-248.
55. Liu, P.; Jamaluddin, M.; Li, K.; Garofalo, R. P.; Casola, A.; Brasier, A. R. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J. Virol., 2007, 81(3), 1401-1411.
56. Higgins, P. G.; Barrow, G. I.; Tyrrell, D. A.; Isaacs, D.; Gauci, C. L. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res., 1990, 14(1), 3-10.
57. Loveys, D. A.; Kulkarni, S.; Atreya, P. L. Role of type I IFNs in the in vitro attenuation of live, temperature-sensitive vaccine strains of human respiratory syncytial virus. Virology, 2000, 271(2), 390-400.
58. Atreya, P. L.; Kulkarni, S. Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology, 1999, 261(2), 227-241.
59. Chipps, B. E.; Sullivan, W. F.; Portnoy, J. M. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr. Infect. Dis. J., 1993, 12(8), 653-658.
60. Aaronson, D. S.; Horvath, C. M. A road map for those who don't know JAK-STAT. Science, 2002, 296(5573), 1653-1655.
61. Levy, D. E.; Garcia-Sastre, A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev., 2001, 12(2-3), 143-156.
62. Le Bon, A.; Tough, D. F. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol., 2002, 14(4), 432-436.
63. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D. F. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol., 2003, 4(10), 1009-1015.
64. Didcock, L.; Young, D. F.; Goodbourn, S.; Randall, R. E. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol., 1999, 73(12), 9928-9933.
65. Ramachandran, A.; Horvath, C. M. Paramyxovirus disruption of interferon signal transduction: STATus report. J. Interferon. Cytokine Res., 2009, 29(9), 531-537.
66. Childs, K.; Stock, N.; Ross, C.; Andrejeva, J.; Hilton, L.; Skinner, M.; Randall, R.; Goodbourn, S. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology, 2006, 80(23), 11723-11732.
67. Guo, Z.; Chen, L. M.; Zeng, H.; Gomez, J. A.; Plowden, J.; Fujita, T.; Katz, J. M.; Donis, R. O.; Sambhara, S. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am. J. Respir. Cell Mol. Biol., 2007, 36(3), 263-269.
68. Mibayashi, M.; Martinez-Sobrido, L.; Loo, Y. M.; Cardenas, W. B.; Gale, M. Jr.; Garcia-Sastre, A. Inhibition of retinoic acidinducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol., 2007, 81(2), 514-524.
69. Opitz, B.; Rejaibi, A.; Dauber, B.; Eckhard, J.; Vinzing, M.; Schmeck, B.; Hippenstiel, S.; Suttorp, N.; Wolff, T. IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein. Cell Microbiol., 2007, 9(4), 930-938.
70. Bao, X.; Liu, T.; Shan, Y.; Li, K.; Garofalo, R. P.; Casola, A. Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathog., 2008, 4(5), e1000077.
71. Ling, Z.; Tran, K. C.; Arnold, J. J.; Teng, M. N. Purification and characterization of recombinant human respiratory syncytial virus nonstructural protein NS1. Protein Expr. Purif., 2008, 57(2), 261-70.
72. Evans, J. E.; Cane, P. A.; Pringle, C. R. Expression and characterisation of the NS1 and NS2 proteins of respiratory syncytial virus. Virus Res., 1996, 43(2), 155-161.
73. Hengst, U.; Kiefer, P. Domains of human respiratory syncytial virus P protein essential for homodimerization and for binding to N and NS1 protein. Virus Genes, 2000, 20(3), 221-225.
74. Atreya, P. L.; Peeples, M. E.; Collins, P. L. The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J. Virol., 1998, 72(2), 1452-1461.
75. Spann, K. M.; Tran, K. C.; Collins, P. L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol., 2005, 79(9), 5353-5362.
76. Bitko, V.; Shulyayeva, O.; Mazumder, B.; Musiyenko, A.; Ramaswamy, M.; Look, D. C.; Barik, S. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NFkappaB-dependent, interferon-independent mechanism and facilitate virus growth. J. Virol., 2007, 81(4), 1786-1795.
77. Bossert, B.; Conzelmann, K. K. Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells. J. Virol., 2002, 76(9), 4287-4293.
78. Schlender, J.; Bossert, B.; Buchholz, U.; Conzelmann, K. K. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J. Virol., 2000, 74(18), 8234-8242.
79. Bossert, B.; Marozin, S.; Conzelmann, K. K. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J. Virol., 2003, 77(16), 8661-8668.
80. Spann, K. M.; Tran, K. C.; Chi, B.; Rabin, R. L.; Collins, P. L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J. Virol., 2004, 78(8), 4363-4369.
81. Ling, Z.; Tran, K. C.; Teng, M. N. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J. Virol., 2009, 83(8), 3734-3742.
82. Swedan, S.; Musiyenko, A.; Barik, S. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J. Virol., 2009, 83(19), 9682-9693.
83. Ramaswamy, M.; Shi, L.; Monick, M. M.; Hunninghake, G. W.; Look, D. C. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol., 2004, 30(6), 893-900.
84. Ramaswamy, M.; Shi, L.; Varga, S. M.; Barik, S.; Behlke, M. A.; Look, D. C. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology, 2006, 344(2), 328-339.
85. Lo, M. S.; Brazas, R. M.; Holtzman, M. J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J. Virol., 2005, 79(14), 9315-9319.
86. Elliott, J.; Lynch, O. T.; Suessmuth, Y.; Qian, P.; Boyd, C. R.; Burrows, J. F.; Buick, R.; Stevenson, N. J.; Touzelet, O.; Gadina, M.; Power, U. F.; Johnston, J. A. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J. Virol., 2007, 81(7), 3428-3436.
87. Moore, E. C.; Barber, J.; Tripp, R. A. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol. J., 2008, 5, 116.
88. Hashimoto, K.; Ishibashi, K.; Ishioka, K.; Zhao, D.; Sato, M.; Ohara, S.; Abe, Y.; Kawasaki, Y.; Sato, Y.; Yokota, S.; Fujii, N.; Peebles, R. S., Jr.; Hosoya, M.; Suzutani, T. RSV replication is attenuated by counteracting expression of the suppressor of cytokine signaling (SOCS) molecules. Virology, 2009, 391(2), 162-170.
89. Teng, M. N.; Collins, P. L. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J. Virol., 1999, 73(1), 466-473.
90. Jin, H.; Zhou, H.; Cheng, X.; Tang, R.; Munoz, M.; Nguyen, N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology, 2000, 273(1), 210-218.
91. Kotelkin, A.; Belyakov, I. M.; Yang, L.; Berzofsky, J. A.; Collins, P. L.; Bukreyev, A. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J. Virol., 2006, 80(12), 5958-5967.
92. Jin, H.; Cheng, X.; Traina-Dorge, V. L.; Park, H. J.; Zhou, H.; Soike, K.; Kemble, G. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine, 2003, 21(25-26), 3647-3652.
93. Teng, M. N.; Whitehead, S. S.; Bermingham, A.; St Claire, M.; Elkins, W. R.; Murphy, B. R.; Collins, P. L. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol., 2000, 74(19), 9317-9321.
94. Whitehead, S. S.; Bukreyev, A.; Teng, M. N.; Firestone, C. Y.; St Claire, M.; Elkins, W. R.; Collins, P. L.; Murphy, B. R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol., 1999, 73(4), 3438-3442.
95. Wright, P. F.; Karron, R. A.; Madhi, S. A.; Treanor, J. J.; King, J. C.; O'Shea, A.; Ikizler, M. R.; Zhu, Y.; Collins, P. L.; Cutland, C.; Randolph, V. B.; Deatly, A. M.; Hackell, J. G.; Gruber, W. C.; Murphy, B. R. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis., 2006, 193(4), 573-581.
96. Munir, S.; Le Nouen, C.; Luongo, C.; Buchholz, U. J.; Collins, P. L.; Bukreyev, A. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J. Virol., 2008, 82(17), 8780-8796.
97. Chang, G. S.; Hong, Y.; Ko, K. D.; Bhardwaj, G.; Holmes, E. C.; Patterson, R. L.; van Rossum, D. B. Phylogenetic profiles reveal evolutionary relationships within the "twilight zone" of sequence similarity. Proc. Natl. Acad. Sci. USA, 2008, 105(36), 13474-13479.
98. Ko, K. D.; Bhardwaj, G.; Hong, Y.; Chang, G. S.; Kiselyov, K.; van Rossum, D. B.; Patterson, R. L. Phylogenetic profiles reveal structural/functional determinants of TRPC3 signal-sensing antennae. Commun. Integr. Biol., 2009, 2(2), 133-137.
99. Hong, Y.; Chalkia, D.; Ko, K. D.; Bhardwaj, G.; Chang, G. S.; van Rossum, D. B.; Patterson, R. L. Phylogenetic Profiles Reveal Structural and Functional Determinants of Lipid-binding. J. Proteomics. Bioinform., 2009, 2, 139-149.
100. Spann, K. M.; Collins, P. L.; Teng, M. N. Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J. Virol., 2003, 77(20), 11201-11211.
101. Luongo, C.; Yang, L.; Winter, C. C.; Spann, K. M.; Murphy, B. R.; Collins, P. L.; Buchholz, U. J. Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine, 2009, 27(41), 5667-5676.